Cargando…
Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glyc...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296185/ https://www.ncbi.nlm.nih.gov/pubmed/30587919 http://dx.doi.org/10.2147/DDDT.S187177 |
_version_ | 1783381000002207744 |
---|---|
author | Zhao, Xiangju Sun, Ying Li, Zhaoguo |
author_facet | Zhao, Xiangju Sun, Ying Li, Zhaoguo |
author_sort | Zhao, Xiangju |
collection | PubMed |
description | PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)-modified cationic nanostructured lipid carriers (NLC) for the delivery of lidocaine (LID; TPGS/LID-NLC). MATERIALS AND METHODS: TPGS/LID-NLC was prepared by solvent diffusion method. The particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, stability, drug release, and cytotoxicity were tested to evaluate the basic characters of NLC. In vitro skin permeation and in vivo anesthesia effect in an animal model were further investigated to determine the therapeutic efficiency of the system. RESULTS: TPGS/LID-NLC had a particle size of 167.6±4.3 nm, a zeta potential of +21.2±2.3 mV, an entrapment efficiency of 85.9%±3.1%, and a drug loading of 11.5%±0.9%. A sustained release pattern was achieved by TPGS/LID-NLC, with 81.2% of LID released at 72 hours. In vitro permeation study showed that the steady-state fluxes (J(ss)), permeability coefficient (Kp), and cumulative drug permeation Q(n) at 72 hours (Q(72)) of TPGS/LID-NLC were 15.6±1.8 µg/cm(2)/hour, 10.3±0.9 cm/hour (×10(−3)), and 547.5±23.6 µg/cm(2), respectively, which were significantly higher than the nonmodified NLC and free drug groups. In vivo anesthesia effect of TPGS/LID-NLC was the most remarkable and long acting among the formulations tested, which could be concluded by the most considerable maximum possible effect from 10 to 120 minutes during the whole research. CONCLUSION: The most prominent in vitro permeation efficiency and in vivo anesthetic effect of TPGS/LID-NLC could be the evidence that TPGS-modified NLC could function as a promising drug delivery system for prolonged and efficient local anesthetic therapy. |
format | Online Article Text |
id | pubmed-6296185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62961852018-12-26 Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system Zhao, Xiangju Sun, Ying Li, Zhaoguo Drug Des Devel Ther Original Research PURPOSE: Transdermal drug delivery of local anesthetics using lipid nanoparticles could enhance lipophilic drugs permeation through the stratum corneum, improve drug diffusion to deeper skin, and exert good therapeutic effects. The purpose of this study was to engineer a Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)-modified cationic nanostructured lipid carriers (NLC) for the delivery of lidocaine (LID; TPGS/LID-NLC). MATERIALS AND METHODS: TPGS/LID-NLC was prepared by solvent diffusion method. The particle size, polydispersity index, zeta potential, drug entrapment efficiency, drug loading, stability, drug release, and cytotoxicity were tested to evaluate the basic characters of NLC. In vitro skin permeation and in vivo anesthesia effect in an animal model were further investigated to determine the therapeutic efficiency of the system. RESULTS: TPGS/LID-NLC had a particle size of 167.6±4.3 nm, a zeta potential of +21.2±2.3 mV, an entrapment efficiency of 85.9%±3.1%, and a drug loading of 11.5%±0.9%. A sustained release pattern was achieved by TPGS/LID-NLC, with 81.2% of LID released at 72 hours. In vitro permeation study showed that the steady-state fluxes (J(ss)), permeability coefficient (Kp), and cumulative drug permeation Q(n) at 72 hours (Q(72)) of TPGS/LID-NLC were 15.6±1.8 µg/cm(2)/hour, 10.3±0.9 cm/hour (×10(−3)), and 547.5±23.6 µg/cm(2), respectively, which were significantly higher than the nonmodified NLC and free drug groups. In vivo anesthesia effect of TPGS/LID-NLC was the most remarkable and long acting among the formulations tested, which could be concluded by the most considerable maximum possible effect from 10 to 120 minutes during the whole research. CONCLUSION: The most prominent in vitro permeation efficiency and in vivo anesthetic effect of TPGS/LID-NLC could be the evidence that TPGS-modified NLC could function as a promising drug delivery system for prolonged and efficient local anesthetic therapy. Dove Medical Press 2018-12-13 /pmc/articles/PMC6296185/ /pubmed/30587919 http://dx.doi.org/10.2147/DDDT.S187177 Text en © 2018 Zhao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Zhao, Xiangju Sun, Ying Li, Zhaoguo Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title | Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title_full | Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title_fullStr | Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title_full_unstemmed | Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title_short | Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
title_sort | topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296185/ https://www.ncbi.nlm.nih.gov/pubmed/30587919 http://dx.doi.org/10.2147/DDDT.S187177 |
work_keys_str_mv | AT zhaoxiangju topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem AT sunying topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem AT lizhaoguo topicalanesthesiatherapyusinglidocaineloadednanostructuredlipidcarrierstocopherylpolyethyleneglycol1000succinatemodifiedtransdermaldeliverysystem |